Naturewise Biotech & Medicals (ROCO:4732) Preferred Stock: NT$0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4732 Naturewise Biotech & Medicals Corp ROCO:4732
57 GF Score
Price NT$16.60
GF Value NT$22.02
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Naturewise Biotech & Medicals Preferred Stock?

Naturewise Biotech & Medicals ROCO:4732 +0.91% 57 Preferred Stock is NT$0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:4732 with a GF Score™ of 57/100 and a GF Value™ of NT$22.02 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. Naturewise Biotech & Medicals's preferred stock for the quarter that ended in Dec. 2025 was NT$0.0 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Naturewise Biotech & Medicals's Enterprise Value for the quarter that ended in Dec. 2025 was NT$543.1 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Naturewise Biotech & Medicals's Book Value per Share for the quarter that ended in Dec. 2025 was NT$12.94.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Naturewise Biotech & Medicals's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was NT$-1.32.


Naturewise Biotech & Medicals  (ROCO:4732) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Naturewise Biotech & Medicals's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Naturewise Biotech & Medicals's Book Value per Share for the quarter that ended in Dec. 2025 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Naturewise Biotech & Medicals's Earnings per Share (Diluted) (EPS) for the six months ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Naturewise Biotech & Medicals Preferred Stock Related Terms


Naturewise Biotech & Medicals Preferred Stock Historical Data

* Premium members only.

The historical data trend for Naturewise Biotech & Medicals's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturewise Biotech & Medicals Preferred Stock Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Naturewise Biotech & Medicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4732
57GF Score
Naturewise Biotech & Medicals Corp ROCO:4732
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturewise Biotech & Medicals Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of NT$0.0 Mil mean?
Naturewise Biotech & Medicals (ROCO:4732) has a Preferred Stock of NT$0.0 Mil as of Dec. 2025. Preferred Stock represents the par value of a company's preferred shares. View historical data on Naturewise Biotech & Medicals and its competitors.
Is Naturewise Biotech & Medicals' Preferred Stock too high?
Naturewise Biotech & Medicals' current Preferred Stock is NT$0.0 Mil. Overall, Naturewise Biotech & Medicals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Preferred Stock compare to VRTX and REGN?
Naturewise Biotech & Medicals' Preferred Stock of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Biotechnology company?
A good Preferred Stock depends on the Biotechnology industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current Preferred Stock is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.02, compared to a current price of NT$16.60 — trading 24.6% below its estimated fair value. The current Preferred Stock is NT$0.0 Mil. Naturewise Biotech & Medicals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Preferred Stock is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?

Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued. The current stock price of NT$16.60 is trading 24.6% below its estimated GF Value™ of NT$22.02. GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.

Key valuation signals for ROCO:4732:

  • Preferred Stock: NT$0.0 Mil
  • GF Value™: NT$22.02 vs. price of NT$16.60 (24.6% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Naturewise Biotech & Medicals Business Description

Address No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
57GF Score

Get the complete analysis for ROCO:4732

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.60
Price
NT$22.02
GF Value